Comparison of BiomeOne and PD-L1 expression tests as a predictor for response to immune checkpoint inhibitors (ICI) in patients with non-small cell lung cancer (NSCLC)

被引：1
|
作者：
Robinson, I. [1 ]
Hochmair, M. J. [1 ]
Ay, L. [1 ]
Absenger, G. [2 ]
Jansen, C. [3 ]
Pacifico, C. [3 ]
Sladek, B. [3 ]
Knabl, A. [3 ]
Gasche, N. [3 ]
Valipour, A. [1 ]
机构：
[1] Karl Landsteiner Inst Lung Res & Pulm Oncol, Vienna, Austria
[2] Graz Univ Klin Innere Med, LKH Univ Klinikum, Graz, Austria
[3] Biome Diagnost GmbH, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 08期
关键词：
D O I：
10.1016/j.annonc.2022.09.056
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
55P
引用
收藏
页码：S1400 / S1400
页数：1
相关论文
共 50 条
  • [21] Dual immune checkpoint blockade for non-small cell lung cancer patients with PD-L1 high expression: calling an end?
    Peng, Ling
    Stebbing, Justin
    Liang, Fei
    Xia, Yang
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (09) : 3858 - 3860
  • [22] Response to letter re: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression
    Ochi, Nobuaki
    Ichihara, Eiki
    Takigawa, Nagio
    Harada, Daijiro
    Inoue, Koji
    Shibayama, Takuo
    Hosokawa, Shinobu
    Kishino, Daizo
    Harita, Shingo
    Oda, Naohiro
    Hara, Naofumi
    Hotta, Katsuyuki
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    EUROPEAN JOURNAL OF CANCER, 2021, 157 : 523 - 524
  • [23] Impact of Brain Metastases in Immune Checkpoint Inhibitors (ICI) Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
    Hendriks, L.
    Henon, C.
    Auclin, E.
    Mezquita, L.
    Ferrara, R.
    Audigier-Valette, C.
    Mazieres, J.
    Lefebyre, C.
    Le Moulec, S.
    Cousin, S.
    Duchemann, B.
    Le Pechoux, C.
    Botticella, A.
    Ammari, S.
    Gazzah, A.
    Caramella, C.
    Adam, J.
    Planchard, D.
    De Ruysscher, D.
    Dingemans, A.
    Besse, B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S384 - S384
  • [24] Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer
    Park, Seongho
    Choi, Yoo-Duk
    Kim, Jieun
    Kho, Bo-Gun
    Park, Cheol-Kyu
    Oh, In-Jae
    Kim, Young-Chul
    THORACIC CANCER, 2020, 11 (02) : 408 - 414
  • [25] Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis
    Zhang, Binbin
    Liu, Yi
    Zhou, Sijing
    Jiang, Huihui
    Zhu, Ke
    Wang, Ran
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 80
  • [26] Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer
    de Miguel-Perez, Diego
    Russo, Alessandro
    Arrieta, Oscar
    Ak, Murat
    Barron, Feliciano
    Gunasekaran, Muthukumar
    Mamindla, Priyadarshini
    Lara-Mejia, Luis
    Peterson, Christine B.
    Er, Mehmet E.
    Peddagangireddy, Vishal
    Buemi, Francesco
    Cooper, Brandon
    Manca, Paolo
    Lapidus, Rena G.
    Hsia, Ru-Ching
    Cardona, Andres F.
    Naing, Aung
    Kaushal, Sunjay
    Hirsch, Fred R.
    Mack, Philip C.
    Serrano, Maria Jose
    Adamo, Vincenzo
    Colen, Rivka R.
    Rolfo, Christian
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
  • [27] Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer
    Diego de Miguel-Perez
    Alessandro Russo
    Oscar Arrieta
    Murat Ak
    Feliciano Barron
    Muthukumar Gunasekaran
    Priyadarshini Mamindla
    Luis Lara-Mejia
    Christine B. Peterson
    Mehmet E. Er
    Vishal Peddagangireddy
    Francesco Buemi
    Brandon Cooper
    Paolo Manca
    Rena G. Lapidus
    Ru-Ching Hsia
    Andres F. Cardona
    Aung Naing
    Sunjay Kaushal
    Fred R. Hirsch
    Philip C. Mack
    Maria Jose Serrano
    Vincenzo Adamo
    Rivka R. Colen
    Christian Rolfo
    Journal of Experimental & Clinical Cancer Research, 41
  • [28] Immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients with WNT pathway mutations (APC/CTNNB1).
    Iranzo, Patricia
    Callejo, Ana
    Pedrola, Anna
    Pardo Aranda, Nuria
    Navarro, Alejandro
    Martinez-Marti, Alex
    Cedres Perez, Susana
    Ros, Javier
    David Assaf, Juan
    Saoudi, Nadia
    Carbonell, Caterina
    Amat, Ramon
    Frigola, Joan
    Jimenez, Jose
    Dienstmann, Rodrigo
    Palmer, Hector G.
    Vivancos, Ana
    Felip, Enriqueta
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] WNT pathway mutations (APC/CTNNB1) and immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients
    Ros Montana, F. J.
    Iranzo, P.
    Pedrola, A.
    Callejo, A.
    Pardo, N.
    Amat, R.
    Carbonell, C.
    Martinez, A.
    Navarro, A.
    Cedres, S.
    Dienstmann, R.
    Palmer, H. G.
    Vivancos, A.
    Felip, E.
    ANNALS OF ONCOLOGY, 2019, 30 : 799 - 799
  • [30] Association of PD-L1 expression with hotspot mutations in non-small cell lung cancer (NSCLC).
    Wan, Renping
    Zhang, Xiaoni
    Qu, Hongyue
    Li, Hui
    Li, Yingmei
    Xu, Mingyan
    Xiao, Yun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345